Raymond Taeyong Chung, M.D.
This page shows the publications co-authored by Raymond Chung and Tracey Simon.
Simon TG, Trejo MEP, McClelland R, Bradley R, Blaha MJ, Zeb I, Corey KE, Budoff MJ, Chung RT. Circulating Interleukin-6 is a biomarker for coronary atherosclerosis in nonalcoholic fatty liver disease: Results from the Multi-Ethnic Study of Atherosclerosis. Int J Cardiol. 2018 05 15; 259:198-204.
Simon TG, Chung RT. Reply. Hepatology. 2016 06; 63(6):2066-7.
Simon TG, Kim AY, Stamm LM, Liu L, Mo H, Doehle B, Pang PS, Brainard DM, McHutchison JG, Gustafson J, Lauer GM, Chung RT. The safety and efficacy of ledipasvir/sofosbuvir for the treatment of a nosocomial outbreak of HCV in patients with significant cardiovascular disease. Antivir Ther. 2016; 21(3):185-94.
Simon TG, Chung RT. The new hepatitis C virus bottleneck: Can delaying therapy be justified? Hepatology. 2015 Sep; 62(3):666-7.
Simon TG, King LY, Chung RT. Reply to: "Coagulation and fibrosis: A potential non-negligible target of statins in chronic hepatitis". J Hepatol. 2015 Jul; 63(1):279.
Simon TG, King LY, Zheng H, Chung RT. Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C. J Hepatol. 2015 Jan; 62(1):18-23.
Simon TG, Duberg AS, Aleman S, Chung RT, Chan AT, Ludvigsson JF. Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality. N Engl J Med. 2020 03 12; 382(11):1018-1028.
Simon TG, Kim MN, Luo X, Yang W, Ma Y, Chong DQ, Fuchs CS, Meyerhardt JA, Corey KE, Chung RT, Stampfer M, Zhang X, Giovannucci EL, Chan AT. Physical activity compared to adiposity and risk of liver-related mortality: Results from two prospective, nationwide cohorts. J Hepatol. 2020 Jun; 72(6):1062-1069.
Simon TG, Duberg AS, Aleman S, Hagstrom H, Nguyen LH, Khalili H, Chung RT, Ludvigsson JF. Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population. Ann Intern Med. 2019 09 03; 171(5):318-327.
Simon TG, Henson J, Osganian S, Masia R, Chan AT, Chung RT, Corey KE. Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2019 12; 17(13):2776-2784.e4.
Simon TG, Deng X, Liu CT, Chung RT, Long MT. The immunity-related GTPase M rs13361189 variant does not increase the risk for prevalent or incident steatosis; results from the Framingham Heart Study. Liver Int. 2019 06; 39(6):1022-1026.
Simon TG, Ma Y, Ludvigsson JF, Chong DQ, Giovannucci EL, Fuchs CS, Meyerhardt JA, Corey KE, Chung RT, Zhang X, Chan AT. Association Between Aspirin Use and Risk of Hepatocellular Carcinoma. JAMA Oncol. 2018 12 01; 4(12):1683-1690.
Simon TG, Van Der Sloot KWJ, Chin SB, Joshi AD, Lochhead P, Ananthakrishnan AN, Xavier R, Chung RT, Khalili H. IRGM Gene Variants Modify the Relationship Between Visceral Adipose Tissue and NAFLD in Patients With Crohn's Disease. Inflamm Bowel Dis. 2018 09 15; 24(10):2247-2257.
Simon TG, Corey KE, Cannon CP, Blazing M, Park JG, O'Donoghue ML, Chung RT, Giugliano RP. The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. Int J Cardiol. 2018 Nov 01; 270:245-252.
Simon TG, King LY, Chong DQ, Nguyen LH, Ma Y, VoPham T, Giovannucci EL, Fuchs CS, Meyerhardt JA, Corey KE, Khalili H, Chung RT, Zhang X, Chan AT. Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies. Hepatology. 2018 05; 67(5):1797-1806.
Simon TG, Bamira DG, Chung RT, Weiner RB, Corey KE. Nonalcoholic Steatohepatitis is Associated with Cardiac Remodeling and Dysfunction. Obesity (Silver Spring). 2017 08; 25(8):1313-1316.
Simon TG, Trejo MEP, Zeb I, Frazier-Wood AC, McClelland RL, Chung RT, Budoff MJ. Coffee consumption is not associated with prevalent subclinical cardiovascular disease (CVD) or the risk of CVD events, in nonalcoholic fatty liver disease: results from the multi-ethnic study of atherosclerosis. Metabolism. 2017 10; 75:1-5.
Simon TG, Kartoun U, Zheng H, Chan AT, Chung RT, Shaw S, Corey KE. MELD-Na score predicts incident major cardiovascular events, in patients with nonalcoholic fatty liver disease (NAFLD). Hepatol Commun. 2017 Jul; 1(5):429-438.
Simon TG, Corey KE, Chung RT, Giugliano R. Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe. Dig Dis Sci. 2016 12; 61(12):3425-3435.
Simon TG, Bonilla H, Yan P, Chung RT, Butt AA. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES. Hepatology. 2016 07; 64(1):47-57.
Johnson KB, Mueller JL, Simon TG, Zheng H, King LY, Makar RS, Gervais DA, Chung RT. Reduced Albumin Dosing During Large-Volume Paracentesis Is Not Associated with Adverse Clinical Outcomes. Dig Dis Sci. 2015 Jul; 60(7):2190-5.
Li DK, Ren Y, Fierer DS, Rutledge S, Shaikh OS, Lo Re V, Simon T, Abou-Samra AB, Chung RT, Butt AA. The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study. Hepatology. 2018 06; 67(6):2244-2253.
Butt AA, Yan P, Simon TG, Chung RT, Abou-Samra AB. Changes in circulating lipids level over time after acquiring HCV infection: results from ERCHIVES. BMC Infect Dis. 2015 Nov 11; 15:510.
Butt AA, Yan P, Bonilla H, Abou-Samra AB, Shaikh OS, Simon TG, Chung RT, Rogal SS. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES. Hepatology. 2015 Aug; 62(2):365-74.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.